Opinion|Videos|November 4, 2024
Targeted Therapies and Biomarkers for SCLC: What’s Next on the Horizon
Panelists discuss how emerging targeted and biomarker-directed therapies are poised to transform the treatment landscape for both limited-stage and extensive-stage small cell lung cancer, highlighting the potential for improved patient outcomes through personalized approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What lies on the horizon for early-phase studies of future, targeted, and/or biomarker-directed therapies for limited-stage and extensive-stage small cell lung cancer?
Advertisement
Related to this article
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
Orelabrutinib Generates Significant Survival Benefits in Treatment-Naive CLL
3
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
4
China’s NMPA Approves Iza-Bren for Pretreated Recurrent/Metastatic ESCC
5